The contractor shall provide preclinical development support for candidate products and drug development activities.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N93022D00009
- Awardee
-
Lovelace Biomedical Research Institute UEI MBT9RXJJ7428
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Preclinical Services for HIV Therapeutics Pre-Solicitation · 75N93019R00021 · Posted Oct 4, 2019
- Last date to order 83% complete
- IDV ceiling
- $107,274,471.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Allergy and Infectious Diseases awarded a single-award Indefinite Delivery Contract to Lovelace Biomedical Research Institute on November 15, 2021, with a ceiling value of $107,274,471 and an ultimate completion date of October 14, 2027. The contract provides preclinical development support for candidate products and drug development activities spanning from initial product discovery through activities required for clinical trials and product licensure.
Place of performance is Albuquerque, New Mexico. The originating solicitation, posted October 4, 2019, sought multiple IDIQs across seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development and clinical dosage manufacturing, preclinical pharmacology and toxicology, and a reagent program for HIV and other infectious diseases. Task Area B for synthesis of therapeutic agents was set aside for small business concerns under NAICS code 541715 with a 1,000 employee size standard. The solicitation anticipated 6–21 task orders annually valued at approximately $500,000 to $5,000,000 each.
Lovelace Biomedical Research Institute is a not-for-profit preclinical contract research organization specializing in advanced preclinical research capabilities across therapeutic areas including animal studies, analytical testing, disease model development, inhalation toxicology, and medical countermeasure testing. The contract operates under Executive Order 14042 and Executive Order 14398.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N93022D00009?
75N93022D00009 was awarded to Lovelace Biomedical Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on November 15, 2021.
How much is contract 75N93022D00009 worth?
75N93022D00009's own ceiling is $107,274,471.
Who can order from contract 75N93022D00009?
75N93022D00009 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N93022D00009 competed?
The extent of competition for 75N93022D00009 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV